Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Management of Low IgA and IgM After Daratumumab Treatment

Infection Prevention and Treatment

  • The National Comprehensive Cancer Network recommends intravenous immunoglobulin (IVIG) therapy for patients with low IgA and IgM levels after daratumumab treatment who experience recurrent or severe infections 1, 2
  • Prophylactic antiviral therapy is recommended for all patients receiving daratumumab to prevent herpes simplex and herpes zoster reactivation, as per the National Comprehensive Cancer Network guidelines 1, 2
  • Testing for hepatitis B is recommended before starting daratumumab to prevent viral reactivation, according to the National Comprehensive Cancer Network 1, 2
  • Three months of antibiotic prophylaxis should be considered at diagnosis for multiple myeloma patients at high risk for infection, as suggested by the National Comprehensive Cancer Network 1, 2

IVIG Administration

  • Standard IVIG dosing is typically 400-600 mg/kg every 3-4 weeks, adjusted based on clinical response, as recommended by the Journal of Allergy and Clinical Immunology 4, 5
  • Monitor renal function, liver enzymes, and complete blood count during IVIG therapy, as advised by the Journal of Allergy and Clinical Immunology 5
  • Patients with paraproteins or cardiovascular risk factors should receive IVIG slowly or consider subcutaneous administration to reduce thrombosis risk, according to the Journal of Allergy and Clinical Immunology 5

Vaccination

  • The National Comprehensive Cancer Network recommends pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine 1 year later to prevent infections 1, 2
  • Vaccine responses may be impaired in patients with hypogammaglobulinemia, particularly those receiving daratumumab, as noted in Leukemia 6